Psychedelics Today8 Joulu 2016

Gabby Agin-Liebes - Can Psilocybin Help Ease Anxiety & Depression for Those Who Are Facing Death?

Download It has been a big week for psychedelic research. Psilocybin and MDMA have made national headlines. The New York Times article, "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients," highlights the recent win for MAPS in regards to their MDMA-assisted psychotherapy research. The FDA has given MAPS the green light to pursue phase 3 research for MDMA-assisted psychotherapy for post-traumatic stress disorder. The New York Times also highlights the recent publications of psilocybin research in the article, "A Dose of a Hallucinogen from a 'Magic Mushroom,' and Then Lasting Peace." Psilocybin has been being researched by various institutions, including NYU and John Hopkins, for its potential therapeutic benefit to combat end-of-life anxiety due to terminal illness and cancer. The study results are fascinating: At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. (http://m.jop.sagepub.com/content/30/12/1165.full) In this episode, Joe and Kyle chat with, Gabby Agin-Liebes, a co-author of the psilocybin study quoted above and a PhD student studying clinical psychology. During the conversation, we get into topics about the recent publication:

Formation of the NYU study
Gabby's role in the study
How volunteers were selected
Inclusion and admission criteria
Study results
Can psilocybin help those who are facing death?
Mystical experiences facilitating and mediating change in depression and anxiety
Current research that Gabby is part of and co-leading
How to get involved in the psychedelic field
Dreams and visions for the future of psychedelics and psychedelic research

About Gabrielle Agin-Liebes: Ms. Agin-Liebes is completing her training toward a PhD in clinical psychology at Palo Alto University. She is a member of PAU's Early Intervention Clinic clinical research laboratory, which provides and evaluates evidence-based treatments to prevent trauma-related problems in recently traumatized individuals. As part of this research laboratory, Ms. Agin-Liebes is examining the effects of trait self-compassion on trauma-related guilt cognitions. Through a supplemental practicum, Gabrielle is training toward a teacher certification in insight oriented mindfulness meditation through the Inner Resources Center at Palo Alto University. Ms. Agin-Liebes' other research focuses on novel and progressive psychotherapies for a variety of clinical indications, with areas of specialty in anxiety, depressive and traumatic stress disorders precipitated by life threatening illnesses. Through the University of California San Francisco (UCSF) Ms. Agin-Liebes is co-leading the qualitative investigation of a pilot study examining the safety and feasibility of Psilocybin-Assisted Supportive-Expressive Group Psychotherapy for demoralization and existential distress in older individuals living with HIV. Prior to beginning her graduate studies, Gabrielle served as Project Manager of the NYU School of Medicine (NYUSoM) Psychedelic Research Laboratory led by Stephen Ross MD in the Department of Psychiatry, where she oversaw the day-to-day operations of trials exploring psilocybin as a treatment for existential distress in cancer patients, and ketamine as a rapidly-acting antidepressant in Emergency Department patients, Through the NYU School of Medicine lab, she has received funding to investigate the qualitative experiences of participants undergoing psilocybin treatment for alcohol dependence and is helping to design a qualitative trial of religious leaders receiving psilocybin at NYUSoM and Johns Hopkins University (JHU). Ms. Agin-Liebes' other research interests include the role of self-compassion in addiction recovery and the therapeutic applications of meditation and mindfulness.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(774)

PT 648 - Enamory - Couples Therapy with Ketamine

Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Kian and Kayla ...

10 Helmi 1h 23min

PT 647 - Joshua White: Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Fireside Project is a nonprofit that helps reduce the risks of psychedelic experiences through a free support line, coaching, education, and research. In this episode, Joshua White speaks with Psyched...

22 Tammi 1h 11min

PT 646 - Manvir Singh: Shamanism the Timeless Religion

Manvir Singh joins Psychedelics Today to unpack what shamanism means and why the term matters now. Singh is an anthropologist and author of Shamanism: The Timeless Religion. He argues that shamanism i...

6 Tammi 1h 8min

PT 645 - Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

Oli Genn-Bash (Brighton, UK) joins Joe Moore for a grounded conversation on the boom in functional mushrooms and why the category may be moving too quickly. As the founder of The Fungi Consultant, Oli...

28 Joulu 20251h 14min

PT 644 - Tricia Eastman: Seeding Consciousness, Ancestral Wisdom, and Psychedelic Initiation

In this live episode, Tricia Eastman joins to discuss Seeding Consciousness: Plant Medicine, Ancestral Wisdom, Psychedelic Initiation. She explains why many Indigenous initiatory systems begin with co...

22 Joulu 20251h 13min

PT 643 - Logan Davidson - American Ibogaine, State Strategy, and the Future of Psychedelic Policy

Logan Davidson joins the show to talk about the fast-moving world of Ibogaine in American and why state-based leadership is shaping the future of psychedelic reform. Davidson is the executive director...

2 Joulu 20251h 16min

PT 642 - Michael Sapiro PhD - Truth Medicine, Psychedelics, and Living Your Truth

In this episode, Michael Sapiro joins Kyle Buller to explore truth, healing, and psychedelic-assisted psychotherapy through the lens of his new book, Truth Medicine. A clinical psychologist, ordained...

28 Marras 20251h 13min

PT 641 - Joe Moore & Kyle Buller - Holotropic Breathwork, Somatics, and Foundations for Psychedelic Work

Holotropic Breathwork sits at the center of this wide ranging conversation between Psychedelics Today co-founders Joe Moore and Kyle Buller. Drawing from decades of personal practice and assorted type...

26 Marras 20251h 5min